List of Excipients in Branded Drug KLOR-CON SPRINKLE

« Back to Dashboard

Generic Drugs Containing KLOR-CON SPRINKLE

Company	Ingredient	NDC	Excipient
Upsher-Smith Laboratories LLC	potassium chloride	0245-5320	ETHYLCELLULOSE
Upsher-Smith Laboratories LLC	potassium chloride	0245-5320	FD&C BLUE NO. 1
Upsher-Smith Laboratories LLC	potassium chloride	0245-5320	FD&C RED NO. 3
Upsher-Smith Laboratories LLC	potassium chloride	0245-5320	GELATIN

What are the Most Frequently-Used Excipients in KLOR-CON SPRINKLE?

# Of NDCs	Excipient
1	D&C YELLOW NO. 10
1	ETHYLCELLULOSE
1	ETHYLCELLULOSES
1	FD&C BLUE NO. 1

Klor-Con Sprinkle Excipient Strategy and Commercial Opportunities

Last updated: October 12, 2026

Klor-Con Sprinkle is an extended-release potassium chloride capsule designed to reduce gastrointestinal irritation and permit administration by sprinkling capsule contents over soft food. Its commercial value rests on formulation execution rather than a differentiated active ingredient. The main opportunities are generic substitution, private-label supply, lower-strength and pediatric presentations, improved excipient systems, and manufacturing platforms that deliver reliable extended release without dose dumping.

What is Klor-Con Sprinkle and how is it regulated?

Klor-Con Sprinkle contains potassium chloride, an electrolyte replacement drug. The dosage form is an extended-release capsule available in 8 mEq and 10 mEq strengths. The product is intended for patients who cannot swallow conventional tablets or capsules but can consume soft food.[1]

Attribute	Klor-Con Sprinkle
Active ingredient	Potassium chloride
Dosage form	Extended-release capsule
Strengths	8 mEq and 10 mEq
Administration	Capsule contents sprinkled on soft food
Release design	Extended release
Regulatory pathway	FDA-approved prescription drug
Therapeutic category	Potassium replacement
Biosimilar exposure	None; potassium chloride is a small molecule
Primary competitive risk	ANDA-based generic competition
Key formulation issue	Controlled release with acceptable gastrointestinal tolerability

Klor-Con Sprinkle is regulated as a conventional small-molecule drug, not a biologic. Biosimilar pathways therefore do not apply. Any competitive product would generally proceed through an abbreviated new drug application, or ANDA, if it can demonstrate pharmaceutical equivalence and bioequivalence.

What excipients are used in Klor-Con Sprinkle?

The product uses excipients associated with pellet manufacture, extended-release coating, capsule filling, and shell integrity. Public labeling identifies inactive ingredients that include microcrystalline cellulose, ethylcellulose, hypromellose, colloidal silicon dioxide, magnesium stearate, and capsule-shell components such as gelatin and colorants.[1]

The excipient system can be divided into four functional groups.

Core and pellet-forming excipients

Microcrystalline cellulose provides bulk, compressibility, and structural support for multiparticulate cores. In a sprinkle product, the core must remain sufficiently robust during filling, transport, and opening of the capsule.

The principal technical requirements are:

• Narrow particle-size distribution
• Low friability
• Consistent potassium chloride loading
• Limited segregation during capsule filling
• Compatibility with aqueous or alcoholic processing, depending on manufacturing design

Potassium chloride is highly water soluble. That property creates a high risk of rapid dissolution if the active is insufficiently embedded or coated. A robust inert core or matrix system is therefore important.

Rate-controlling polymers

Ethylcellulose is commonly used as a water-insoluble release-controlling polymer. Hypromellose can function as a film former, pore-forming polymer, viscosity modifier, or release-modifying component. The combination allows the manufacturer to tune water ingress and potassium chloride diffusion.

The commercial formulation challenge is balance. Excessive coating can delay release and reduce dose availability. Insufficient coating can produce rapid release, gastrointestinal irritation, or a pharmacokinetic profile that fails bioequivalence testing.

Processing aids

Colloidal silicon dioxide can improve powder flow and reduce cohesion. Magnesium stearate can support manufacturing by reducing adhesion to equipment. Both require process control because excessive lubricant or glidant levels can affect wetting, coating adhesion, dissolution, or content uniformity.

Capsule-shell excipients

Gelatin provides the capsule shell. Titanium dioxide and approved colorants support product identification and appearance. Capsule-shell composition matters commercially because some patients avoid gelatin for religious, dietary, or allergy-related reasons. A vegetarian hydroxypropyl methylcellulose shell could create a differentiated product, although the change would require comparative quality and stability work.

What formulation patents protect Klor-Con Sprinkle?

Publicly available FDA labeling identifies the formulation and inactive ingredients but does not establish a currently enforceable patent estate. The product’s commercial protection appears to depend more on regulatory approval, manufacturing know-how, trademarks, and market familiarity than on a clearly identifiable active patent covering the marketed product.

The relevant legal distinction is between:

1. Patents listed in the FDA Orange Book for the reference product.
2. Expired patents that may explain historical development.
3. Unlisted process, manufacturing, or trade-secret protections.
4. New patents covering an improved formulation, coating process, capsule shell, or administration method.

A competitor should review the current Orange Book entry for the applicable Klor-Con Sprinkle NDA and confirm whether any patent or exclusivity information remains listed.[2] A product with no active Orange Book-listed patents presents a different challenge from a product protected by multiple formulation or method-of-use patents.

Are there method-of-use patents for Klor-Con Sprinkle?

Potassium chloride replacement uses are established and broad. A generic applicant would not normally face a strong method-of-use patent barrier merely because the product is used to treat or prevent hypokalemia. Narrower claims could be relevant if they cover a specific patient population, administration protocol, food vehicle, or dosing regimen.

No commercially significant method-of-use patent position can be inferred from the product label alone. Regulatory labeling and patent claims must be reviewed separately.

When does Klor-Con Sprinkle lose exclusivity?

Klor-Con Sprinkle’s core active ingredient, potassium chloride, has been generic for decades. The relevant commercial question is not loss of active-ingredient exclusivity but the availability and competitiveness of approved extended-release sprinkle products.

FDA market entry can occur through an ANDA if a sponsor demonstrates that its product is pharmaceutically equivalent and bioequivalent to the reference listed drug. FDA approval of a generic potassium chloride extended-release capsule does not require a new clinical efficacy program comparable to an NDA.

The practical exclusivity timeline is therefore driven by:

Event	Commercial effect
NDA approval	Establishes the reference product
NDA exclusivity expiration	Removes any remaining FDA exclusivity barrier
Patent expiration or absence of listed patents	Reduces litigation risk
ANDA approval	Enables generic entry
Commercial launch	Determines actual price and share erosion
Supply disruption or shortage	Can temporarily improve branded or authorized-generic demand

The reference product may retain commercial value after formal exclusivity ends because potassium chloride products have meaningful formulation and tolerability differences. Physicians and pharmacists may continue to distinguish sprinkle capsules from conventional extended-release tablets.

What is the Orange Book status of Klor-Con Sprinkle?

The Orange Book is the controlling source for current patent listings, therapeutic-equivalence evaluations, and reference-product status.[2] Klor-Con Sprinkle should be evaluated by NDA number, strength, dosage form, and manufacturer rather than by brand name alone.

A due-diligence review should assess:

• Whether the 8 mEq and 10 mEq strengths are listed under the same NDA.
• Whether the product has an active reference-listed-drug designation.
• Whether any patents are listed.
• Whether the product has active exclusivity.
• Whether approved generic products have an AB rating.
• Whether any listed patent has a delayed generic-entry date.

Without an active listed patent or exclusivity period, a Paragraph IV filing would not be the principal route to market entry. A generic sponsor could still file an ANDA using an appropriate certification, but the litigation trigger would depend on the patent certifications submitted and any listed claims.

Which companies are challenging Klor-Con Sprinkle?

Public FDA product data and labeling do not by themselves establish current Paragraph IV litigation against Klor-Con Sprinkle. Generic potassium chloride products are marketed by multiple manufacturers, but the existence of an approved competitor does not prove that the sponsor challenged a patent or that litigation occurred.

The competitive landscape includes:

• Branded Klor-Con Sprinkle.
• Generic potassium chloride extended-release capsules.
• Potassium chloride extended-release tablets.
• Liquid potassium chloride products.
• Intravenous potassium chloride for supervised clinical use.
• Other sprinkle or multiparticulate electrolyte products.

A competitor’s commercial advantage will depend on pharmacy substitution, wholesale acquisition cost, supply reliability, and whether the product matches the reference product’s administration instructions.

What formulation strategies could improve Klor-Con Sprinkle?

The strongest development opportunities involve usability, release control, and patient acceptability.

Vegetarian capsule shells

Replacing gelatin with hypromellose could broaden market access among vegetarian, vegan, religious, and selected institutional customers. The sponsor would need to address shell moisture, brittleness, dissolution, stability, and capsule-opening behavior.

Improved sprinkle performance

A differentiated product could optimize pellet size, mouthfeel, static behavior, and adherence to soft food. The contents must disperse without clumping and must remain acceptable when mixed with applesauce or another validated vehicle.

Lower-strength dosing

Additional strengths could improve titration for patients with mild hypokalemia, renal impairment, or changing potassium requirements. Any new strength would require dose proportionality, content uniformity, stability, and labeling support.

Reduced gastrointestinal irritation

A more uniform multiparticulate coating could reduce local potassium concentration and improve tolerability. A formulation that maintains extended release while reducing nausea, abdominal discomfort, or mucosal irritation could support switching and premium pricing.

Excipient substitution

Potential substitutions include:

• Hypromellose for selected film-coating functions
• Alternative water-insoluble polymers
• Low-moisture glidants
• Directly compressible or extrudable core materials
• Non-gelatin capsule shells
• Colorant-free shells for sensitive populations

Each substitution creates regulatory comparability work. Excipients that alter release kinetics are higher risk than cosmetic or shell-color changes.

What manufacturing and intellectual-property barriers exist?

The active ingredient is inexpensive and widely available. The manufacturing barrier is process reproducibility.

Critical process parameters include:

• Potassium chloride particle-size distribution
• Core density and porosity
• Drug loading
• Coating weight gain
• Polymer-to-pore-former ratio
• Drying temperature and endpoint
• Residual solvent or moisture
• Pellet segregation
• Capsule fill-weight variation
• Dissolution at multiple pH conditions

The most defensible intellectual property would likely cover a specific multiparticulate architecture, coating composition, release profile, manufacturing process, or food-administration method. Trade secrets may be more important than patents if the formulation relies on process settings that are difficult to reverse engineer.

A new patent estate would be stronger if it claimed measurable technical advantages, such as a defined dissolution profile, reduced dose dumping under alcohol exposure, improved stability at high humidity, or improved administration through a validated food vehicle.

How strong is the commercial opportunity?

The commercial opportunity is moderate, with the strongest value in operational execution rather than premium active-ingredient pricing.

Opportunity	Commercial attractiveness	Main barrier
Generic extended-release capsules	Moderate	Bioequivalence and price competition
Authorized generic	Moderate to high	Contracting and supply economics
Vegetarian capsule	Moderate	Stability and patient acceptance
New strengths	Moderate	Regulatory and manufacturing cost
Pediatric-friendly sprinkle product	Moderate	Safety, labeling, and palatability
Improved gastrointestinal tolerability	High if demonstrated	Clinical or comparative evidence
Private-label institutional supply	Moderate	Procurement pricing
Novel potassium multiparticulate platform	High strategic value	Development cost and competition

Revenue exposure cannot be reliably quantified at the individual Klor-Con Sprinkle product level from public FDA sources. The product’s value is more likely to be concentrated in prescription volume, pharmacy substitution, and supply continuity than in a high-margin specialty-drug model.

What FDA regulatory requirements apply?

A reformulated or competing product must satisfy applicable requirements for identity, strength, quality, purity, stability, dissolution, and bioequivalence. FDA’s ANDA framework is the likely route for a conventional generic equivalent.[3]

The sponsor must also control potassium-related safety risks. Excess potassium can cause hyperkalemia, particularly in patients with renal impairment or those receiving renin-angiotensin-aldosterone system inhibitors, potassium-sparing diuretics, or other potassium-retaining therapies.[1]

Labeling must preserve administration controls. Patients should not crush or chew extended-release contents. The product should be administered according to the approved instructions, including the validated soft-food vehicle and immediate consumption requirements.

What generic launch scenarios exist?

Three launch scenarios are commercially plausible.

Price-led generic entry

Several ANDA sponsors enter with comparable extended-release capsules. Pharmacy substitution increases, branded pricing declines, and the reference product retains a smaller share through prescriber familiarity.

Differentiated generic entry

One sponsor launches a vegetarian capsule, new strength, improved packaging, or more reliable supply. The product commands limited premium value while remaining below the brand price.

Supply-constrained market

Manufacturing disruption at one or more suppliers creates temporary demand for the reference product or authorized generic. Potassium chloride products require dependable supply because substitution options may not match dosage form or patient administration needs.

Key Takeaways

• Klor-Con Sprinkle is an extended-release potassium chloride capsule available in 8 mEq and 10 mEq strengths.
• Its excipient strategy relies on multiparticulate cores, ethylcellulose and hypromellose release control, flow aids, lubricants, and capsule-shell materials.
• The main commercial barrier is reproducible extended-release performance, not active-ingredient sourcing.
• Biosimilar risk does not apply; generic competition through ANDAs is the relevant pathway.
• A current Orange Book review is necessary to confirm any active patents, exclusivity, or Paragraph IV exposure.
• The most credible lifecycle opportunities are vegetarian shells, additional strengths, improved sprinkle behavior, lower gastrointestinal irritation, and stronger supply reliability.
• A new patent estate would be most defensible around a specific coating architecture, dissolution profile, process, or food-administration method.

FAQs About Klor-Con Sprinkle Excipient and Commercial Strategy

Can Klor-Con Sprinkle contents be mixed with applesauce?

The product is designed to be sprinkled over soft food under the approved labeling instructions. The contents should not be crushed or chewed, and the mixture should be consumed as directed.[1]

Is Klor-Con Sprinkle interchangeable with Klor-Con M tablets?

No. Both products contain potassium chloride, but their dosage forms, release mechanisms, administration instructions, and labeled strengths may differ. Substitution should follow FDA therapeutic-equivalence designations and applicable pharmacy rules.

Does Klor-Con Sprinkle have biosimilar competition?

No. Potassium chloride is a small-molecule active ingredient. Competitive products are generally evaluated through generic-drug pathways rather than the biosimilar pathway.

Can a new potassium chloride sprinkle formulation receive patent protection?

Yes. Patent protection could cover a novel multiparticulate structure, coating system, release profile, capsule shell, manufacturing process, or validated administration method. Broad claims covering potassium chloride alone would face substantial prior-art risk.

What is the most attractive excipient innovation for a competing product?

A stable non-gelatin capsule combined with robust multiparticulate coating and improved food dispersion offers the clearest differentiation. The product would still need to meet FDA quality and bioequivalence requirements.

References

1. DailyMed. (n.d.). Klor-Con Sprinkle: Potassium chloride extended-release capsules prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process.
4. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.